Key Highlights
The TUXEDO-2 trial represents the first head-to-head comparison of potent P2Y12 inhibitors in a specifically diabetic, multivessel disease population undergoing percutaneous coronary intervention (PCI). The study found that ticagrelor failed to demonstrate noninferiority to prasugrel for the composite endpoint of death, myocardial infarction, stroke, or major bleeding at 1 year. Numerically higher event rates were observed across all components with ticagrelor, though differences did not reach statistical significance. These findings carry important implications for antiplatelet therapy selection in this high-risk subgroup.
